IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones

Virology

Volumn 407, Issue 1, 2010, Pages 80-90

  Suda, Goki ^a   Sakamoto, Naoya ^a   Itsui, Yasuhiro ^a,c   Nakagawa, Mina ^a   Tasaka Fujita, Megumi ^a   Funaoka, Yusuke ^a   Watanabe, Takako ^a   Nitta, Sayuri ^a   Kiyohashi, Kei ^a   Azuma, Seishin ^a   Kakinuma, Sei ^a   Tsuchiya, Kiichiro ^a   Imamura, Michio ^b   Hiraga, Nobuhiko ^b   Chayama, Kazuaki ^b   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Soka Municipal Hospital   (Japan)

Author keywords

HCV JFH1; Inter genotypic chimeric virus; Interleukin 6; SOCS3

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MYXOVIRUS RESISTANCE PROTEIN A; PROTEIN 25 OAS; RECOMBINANT ALPHA2B INTERFERON; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; ALPHA INTERFERON; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHIMERA; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MALE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; UPREGULATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TYPING; CASE REPORT; CELL LINE; GENETIC RECOMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; IMMUNOLOGY;

ADULT; CELL LINE; GENOTYPE; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-6; MALE; RECOMBINATION, GENETIC; RNA, VIRAL;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 2;

EID: 77956908091     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.07.041     Document Type: Article

References (44)

1. Alter M.J. Epidemiology of hepatitis C. Hepatology 1997, 26(3 Suppl 1):62S-65S.
2. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290(5498):1972-1974.
3. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., Heinrich P.C., Haussinger D. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 2003, 17(3):488-490.
4. Bukh J., Miller R.H., Purcell R.H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 1995, 15(1):41-63.
5. Chang K.C., Hansen E., Foroni L., Lida J., Goldspink G. Molecular and functional analysis of the virus- and interferon-inducible human MxA promoter. Arch. Virol. 1991, 117(1-2):1-15.
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347(13):975-982.
7. Gottwein J.M., Scheel T.K., Hoegh A.M., Lademann J.B., Eugen-Olsen J., Lisby G., Bukh J. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 2007, 133(5):1614-1626.
8. Gottwein J.M., Scheel T.K., Jensen T.B., Lademann J.B., Prentoe J.C., Knudsen M.L., Hoegh A.M., Bukh J. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009, 49(2):364-377.
9. Hanada T., Kinjyo I., Inagaki-Ohara K., Yoshimura A. Negative regulation of cytokine signaling by CIS/SOCS family proteins and their roles in inflammatory diseases. Rev. Physiol. Biochem. Pharmacol. 2003, 149:72-86.
10. He Y., Katze M.G. To interfere and to anti-intefere: the interplay between hepatitis C virus and interferon. Viral Immunol. 2002, 15:95-119.
11. Hoffmann M., Zeisel M.B., Jilg N., Paranhos-Baccala G., Stoll-Keller F., Wakita T., Hafkemeyer P., Blum H.E., Barth H., Henneke P., Baumert T.F. Toll-Like Receptor 2 Senses Hepatitis C Virus Core Protein but Not InfectiousViral Particles. J. Innate Immun. 2009, 1(No. 5):446-454.
12. Hoofnagle J.H., di Bisceglie A.M. The treatment of chronic viral hepatitis. N. Engl. J. Med. 1997, 336(5):347-356.
13. Itsui Y., Sakamoto N., Kakinuma S., Nakagawa M., Sekine-Osajima Y., Tasaka-Fujita M., Nishimura-Sakurai Y., Suda G., Karakama Y., Yamamoto M., Watanabe T., Ueyama M., Funaoka Y., Azuma S., Watanabe M. Antiviral effects of the interferon-induced protein GBP-1 and its interaction with the hepatitis C virus NS5B protein. Hepatology 2009, 50(6):1727-1737.
14. Itsui Y., Sakamoto N., Kurosaki M., Kanazawa N., Tanabe Y., Koyama T., Takeda Y., Nakagawa M., Kakinuma S., Sekine Y., Maekawa S., Enomoto N., Watanabe M. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J. Viral Hepat. 2006, 13(10):690-700.
15. Jensen T.B., Gottwein J.M., Scheel T.K., Hoegh A.M., Eugen-Olsen J., Bukh J. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 2008, 198(12):1756-1765.
16. Kalvakolanu D.V. Alternate interferon signaling pathways. Pharmacol. Ther. 2003, 100(1):1-29.
17. Kato T., Date T., Miyamoto M., Furusaka A., Tokushige K., Mizokami M., Wakita T. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003, 125(6):1808-1817.
18. Kawaguchi T., Yoshida T., Harada M., Hisamoto T., Nagao Y., Ide T., Taniguchi E., Kumemura H., Hanada S., Maeyama M., Baba S., Koga H., Kumashiro R., Ueno T., Ogata H., Yoshimura A., Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol. 2004, 165(5):1499-1508.
19. Lin W., Choe W.H., Hiasa Y., Kamegaya Y., Blackard J.T., Schmidt E.V., Chung R.T. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology 2005, 128(4):1034-1041.
20. Lin W., Kim S.S., Yeung E., Kamegaya Y., Blackard J.T., Kim K.A., Holtzman M.J., Chung R.T. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J. Virol. 2006, 80(18):9226-9235.
21. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309(5734):623-626.
22. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285(5424):110-113.
23. Malaguarnera M., Di Fazio I., Romeo M.A., Restuccia S., Laurino A., Trovato B.A. Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. J. Gastroenterol. 1997, 32(2):211-215.
24. Miyaaki H., Ichikawa T., Nakao K., Matsuzaki T., Muraoka T., Honda T., Takeshita S., Shibata H., Ozawa E., Akiyama M., Miuma S., Eguchi K. Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol. Res. 2009, 39(9):850-855.
25. Morikawa K., Zhao Z., Date T., Miyamoto M., Murayama A., Akazawa D., Tanabe J., Sone S., Wakita T. The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. J. Med. Virol. 2007, 79(6):714-723.
26. Mozer-Lisewska I., Sluzewski W., Kaczmarek M., Jenek R., Szczepanski M., Figlerowicz M., Kowala-Piaskowska A., Zeromski J. Tissue localization of Toll-like receptors in biopsy specimens of liver from children infected with hepatitis C virus. Scand. J. Immunol. 2005, 62(4):407-412.
27. Murayama A., Date T., Morikawa K., Akazawa D., Miyamoto M., Kaga M., Ishii K., Suzuki T., Kato T., Mizokami M., Wakita T. The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells. J. Virol. 2007, 81(15):8030-8040.
28. Pietschmann T., Kaul A., Koutsoudakis G., Shavinskaya A., Kallis S., Steinmann E., Abid K., Negro F., Dreux M., Cosset F.L., Bartenschlager R. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 2006, 103(19):7408-7413.
29. Polyak S.J., Khabar K.S., Rezeiq M., Gretch D.R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 2001, 75(13):6209-6211.
30. Ramadori G., Christ B. Cytokines and the hepatic acute-phase response. Semin. Liver Dis. 1999, 19(2):141-155.
31. Ronni T., Matikainen S., Lehtonen A., Palvimo J., Dellis J., Van Eylen F., Goetschy J.F., Horisberger M., Content J., Julkunen I. The proximal interferon-stimulated response elements are essential for interferon responsiveness: a promoter analysis of the antiviral MxA gene. J. Interferon Cytokine Res. 1998, 18(9):773-781.
32. Sabio G., Das M., Mora A., Zhang Z., Jun J.Y., Ko H.J., Barrett T., Kim J.K., Davis R.J. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322(5907):1539-1543.
33. Samuel C. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14(4):778-809.
34. Scheel T.K., Gottwein J.M., Jensen T.B., Prentoe J.C., Hoegh A.M., Alter H.J., Eugen-Olsen J., Bukh J. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. USA 2008, 105(3):997-1002.
35. Sekine-Osajima Y., Sakamoto N., Mishima K., Nakagawa M., Itsui Y., Tasaka M., Nishimura-Sakurai Y., Chen C.H., Kanai T., Tsuchiya K., Wakita T., Enomoto N., Watanabe M. Development of plaque assays for hepatitis C virus-JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacity. Virology 2008, 371(1):71-85.
36. Song M.M., Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J. Biol. Chem. 1998, 273(52):35056-35062.
37. Tanabe Y., Sakamoto N., Enomoto N., Kurosaki M., Ueda E., Maekawa S., Yamashiro T., Nakagawa M., Chen C.H., Kanazawa N., Kakinuma S., Watanabe M. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha. J. Infect. Dis. 2004, 189(7):1129-1139.
38. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 2001, 19:623-655.
39. Taniguchi T., Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr. Opin. Immunol. 2002, 14:111-116.
40. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285(5424):107-110.
41. Vlotides G., Sorensen A.S., Kopp F., Zitzmann K., Cengic N., Brand S., Zachoval R., Auernhammer C.J. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2, 5-OAS and MxA. Biochem. Biophys. Res. Commun. 2004, 320(3):1007-1014.
42. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11(7):791-796.
43. Walsh M.J., Jonsson J.R., Richardson M.M., Lipka G.M., Purdie D.M., Clouston A.D., Powell E.E. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55(4):529-535.
44. Zhu H., Nelson D.R., Crawford J.M., Liu C. Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. J. Interferon Cytokine Res. 2005, 25(9):528-539.